REG - e-Therapeutics plc - Appointment of Chief Financial Officer

E-TherapeuticsAnnouncement

29/03/2021 07:05

RNS Number : 7181T
  
e-Therapeutics plc
  
29 March 2021
  
 

 
e-therapeutics plc
 
("e-therapeutics" or the "Company")
 
Appointment of Chief Financial Officer
 
 
Oxford, UK, 29 March 2021: e-therapeutics plc (AIM: ETX.L) today announces the appointment of Dr Karl Keegan as Chief Financial Officer ("CFO") effective immediately. The CFO role will be a non-board position. 
 
Dr Keegan brings a depth of capital market and strategic financing experience with over 20 years' experience in the pharmaceutical and biotech industries. After working in academia and large pharma, Karl became a highly rated sell-side analyst at a number of investment banks. Since 2009, he has held senior executive roles in private and public companies, most recently as Chief Executive Officer of privately held Hox Therapeutics Limited.
 
Karl received his BSc in Pharmacology from University College Dublin, MPhil and PhD degrees from the University of Cambridge and his MSc (Finance) from London Business School. 
 
Dr Keegan, Chief Financial Officer, said: "I am delighted to be joining the e-therapeutics team at such a pivotal time for the Company. The Company has built an impressive computational biology drug discovery platform and clinically validated RNA interference drug modality."
 
Ali Mortazavi, Chief Executive Officer, commented: "We are delighted to welcome Karl to e-therapeutics at this point in the Company's evolution. The combination of his industry and financial sector expertise will be a major addition to the team."
 
 
Enquiries:



e-therapeutics plc








Ali Mortazavi, CEO 


Tel: +44 (0)1993 883 125








www.etherapeutics.co.uk














SP Angel Corporate Finance LLP


Tel: +44(0)20 3470 0470




Nominated Adviser and Broker








Matthew Johnson/Caroline Rowe (Corporate Finance)








Vadim Alexandre/Rob Rees (Corporate Broking)

















About e-therapeutics plc
 
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
 
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
 
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOABLGDXCSDDGBR